Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 475

1.

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: A multicenter retrospective study.

Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F.

J Eur Acad Dermatol Venereol. 2018 Oct 14. doi: 10.1111/jdv.15288. [Epub ahead of print]

PMID:
30317679
2.

Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study.

Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, Soria C, Belinchón I, de la Cueva P, Ferrán M, Carrascosa JM, Gómez FJ, Salgado L, Velasco M, Descalzo MA, García-Doval I, Daudén E; BIOBADADERM Study Group and Psoriasis Group of the AEDV.

J Dermatolog Treat. 2018 Oct 11:1-23. doi: 10.1080/09546634.2018.1535690. [Epub ahead of print]

PMID:
30307344
3.

[Introduction].

Carrascosa JM.

Rev Alerg Mex. 2018;65 Suppl 2:s7-s8. doi: 10.29262/ram.v65i6.556. Spanish. No abstract available.

PMID:
30278477
4.

Mechanics of Virus-like Particles Labeled with Green Fluorescent Protein.

Mertens J, Bondia P, Allende-Ballestero C, Carrascosa JL, Flors C, Castón JR.

Biophys J. 2018 Sep 1. pii: S0006-3495(18)31012-9. doi: 10.1016/j.bpj.2018.08.035. [Epub ahead of print]

PMID:
30249401
5.

Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.

Notario J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, Rocamora V, Carrascosa JM, Del Alcázar E, Alsina M, Vidal D, Puig L, López-Ferrer A, Riera J, Gallardo F, Ferran M.

J Dermatolog Treat. 2018 Sep 22:1-21. doi: 10.1080/09546634.2018.1528000. [Epub ahead of print]

PMID:
30244618
6.

Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation.

Mingorance L, Castro V, Ávila-Pérez G, Calvo G, Rodriguez MJ, Carrascosa JL, Pérez-Del-Pulgar S, Forns X, Gastaminza P.

PLoS Pathog. 2018 Sep 18;14(9):e1007284. doi: 10.1371/journal.ppat.1007284. eCollection 2018 Sep.

7.

X-ray structure of full-length human RuvB-Like 2 - mechanistic insights into coupling between ATP binding and mechanical action.

Silva STN, Brito JA, Arranz R, Sorzano CÓS, Ebel C, Doutch J, Tully MD, Carazo JM, Carrascosa JL, Matias PM, Bandeiras TM.

Sci Rep. 2018 Sep 13;8(1):13726. doi: 10.1038/s41598-018-31997-z.

8.

The RNA-binding protein of a double-stranded RNA virus acts like a scaffold protein.

Mata CP, Mertens J, Fontana J, Luque D, Allende-Ballestero C, Reguera D, Trus BL, Steven AC, Carrascosa JL, Castón JR.

J Virol. 2018 Jul 18. pii: JVI.00968-18. doi: 10.1128/JVI.00968-18. [Epub ahead of print]

PMID:
30021893
9.

Position statement for the management of comorbidities in psoriasis.

Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, Jodar E, Joven B, Lázaro P, Olveira A, Quintero J, Rivera R.

J Eur Acad Dermatol Venereol. 2018 Jul 10. doi: 10.1111/jdv.15177. [Epub ahead of print]

PMID:
29992631
10.

Paradoxical eczematous reaction to ixekizumab.

Munera-Campos M, Ballesca F, Richarz N, Ferrandiz C, Carrascosa JM.

J Eur Acad Dermatol Venereol. 2018 Jun 28. doi: 10.1111/jdv.15156. [Epub ahead of print] No abstract available.

PMID:
29953678
11.

Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature.

Munera-Campos M, Ballesca F, Carrascosa JM.

Actas Dermosifiliogr. 2018 Jun 11. pii: S0001-7310(18)30200-X. doi: 10.1016/j.ad.2018.04.003. [Epub ahead of print] English, Spanish.

PMID:
29903464
12.

Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.

Zozaya N, Martínez-Galdeano L, Alcalá B, Armario-Hita JC, Carmona C, Carrascosa JM, Herranz P, Lamas MJ, Trapero-Bertran M, Hidalgo-Vega Á.

BioDrugs. 2018 Jun;32(3):281-291. doi: 10.1007/s40259-018-0284-3.

13.

Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.

Toro-Montecinos M, Ballescá F, Ferrandiz C, Teniente-Serra A, Martinez-Caceres E, Carrascosa JM.

J Dermatolog Treat. 2018 May 10:1-5. doi: 10.1080/09546634.2018.1468065. [Epub ahead of print]

PMID:
29683393
14.

Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis.

Carrascosa JM, Rebollo F, Gómez S, De-la-Cueva P.

J Dermatolog Treat. 2018 May 8:1-6. doi: 10.1080/09546634.2018.1467536. [Epub ahead of print]

PMID:
29671665
15.

Direct visualization of single virus restoration after damage in real time.

de Pablo PJ, Hernando-Pérez M, Carrasco C, Carrascosa JL.

J Biol Phys. 2018 Jun;44(2):225-235. doi: 10.1007/s10867-018-9492-9. Epub 2018 Apr 13.

PMID:
29654426
16.

The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.

Villanueva L, Silva L, Llopiz D, Ruiz M, Iglesias T, Lozano T, Casares N, Hervas-Stubbs S, Rodríguez MJ, Carrascosa JL, Lasarte JJ, Sarobe P.

Oncoimmunology. 2017 Dec 21;7(4):e1409321. doi: 10.1080/2162402X.2017.1409321. eCollection 2018.

PMID:
29632721
17.

Corrigendum to "Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis" [89 (March (3)) (2018) 301-304].

Julià M, Consuegra-Fernández M, Guilabert A, Muñoz C, Esteve A, Armiger-Borràs N, Santiago F, Arias MT, Romaní J, Ferrándiz C, Carrascosa JM, Pedrosa E, Alsina-Gibert M, Lozano F, Mascaró-Galy JM.

J Dermatol Sci. 2018 Sep;91(3):342. doi: 10.1016/j.jdermsci.2018.03.013. Epub 2018 Apr 1. No abstract available.

PMID:
29615327
18.

New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.

Carrascosa JM, Del-Alcazar E.

Expert Rev Clin Immunol. 2018 Apr;14(4):259-273. doi: 10.1080/1744666X.2018.1454835. Epub 2018 Mar 28.

PMID:
29557200
19.

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.

Carrascosa JM, Jacobs I, Petersel D, Strohal R.

Dermatol Ther (Heidelb). 2018 Jun;8(2):173-194. doi: 10.1007/s13555-018-0230-9. Epub 2018 Mar 16. Review.

20.

Tuning Optoelectronic and Chiroptic Properties of Peptide-Based Materials by Controlling the Pathway Complexity.

López-Andarias A, López-Andarias J, Atienza C, Chichón FJ, Carrascosa JL, Martín N.

Chemistry. 2018 May 28;24(30):7755-7760. doi: 10.1002/chem.201801238. Epub 2018 May 3.

PMID:
29537693

Supplemental Content

Loading ...
Support Center